With Prevnar Challenger Fully Funded, Affinivax Raises $120m For Other Novel Vaccines

 
• By Mandy Jackson

Astellas is funding the company’s Phase II vaccine against 24 pneumococcal serotypes. Affinivax will use its series B venture cash to advance its MAPS vaccines for bacterial and viral infections and cancer.

Vaccine vial dose flu shot drug needle syringe,medical concept vaccination hypodermic injection treatment disease care hospital prevention immunization illness disease baby child.blue background
Affinivax is developing pneumococcal and other vaccines with its MAPS platform • Source: Shutterstock

More from Financing

More from Business